All In Biotech

Drug Trial Radar · NCT07946913

A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines

A Multicenter, Randomized, Double-Blind, Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 514 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

514

Planned (sponsor's estimate)

Start

Dec 7, 2026

Primary completion

Mar 24, 2028

Study completion Jan 26, 2029

Sponsor

Lead sponsor
Longbio PharmaIndustry
Sponsor type
Industry
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, active-controlled Phase III clinical study to evaluate the safety and efficacy of LP-003 injection in patients with chronic spontaneous urticaria who remain symptomatic despite treatment with H1 antihistamines.

Conditions

  • Chronic Spontaneous Urticaria (CSU)

Interventions

  • LP-003 InjectionBiological

    s.c. injection

  • OmalizumabBiological

    s.c. injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in weekly Urticaria Activity Score (UAS7) at week 12Time frame: Week 12

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, China

  • The First Affiliated Hospital of China Medical University

    Shenyang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.